Urticaria Centers of Reference and Excellence (UCARE) 2023 | São Paulo

• Enhance awareness of emerging clinical trial data in CSU
• Learn about the role of type 2 inflammation in the pathogenesis of CSU
• Explore the role of the neuroimmune axis in CSU

Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

Symposium focusing on the key roles of type 2 inflammation and the neuroimmune axis in CSU pathophysiology. Current understanding of these pathways has guided development of emerging therapeutics that target molecular drivers within type 2 inflammation, from which Phase 3 efficacy and safety data are presented and explored. Dr. Ensina guides discussions on the perspective of CSU management in Brazil. Dr. Maurer explores current clinical data from leading emerging therapies in CSU. Drs. Saini and Kim provide a deep dive into the pathophysiology of type 2 inflammation and the neuroimmune axis in CSU.

Agenda:

1. Welcome & Introduction, Marcus Maurer (Chair)

2. CSU – The Brazil Perspective, Luis Felipe Ensina

3. Emerging Clinical Trial Data in CSU, Marcus Maurer

4. Role of Type 2 Inflammation in CSU Pathogenesis, Sarbjit Saini

5. Neuronal Involvement in CSU, Brian Kim

6. Panel Discussion/Q&A, All faculty

MAT-GLB-2303901 V1 12/2023